Articles sur biosimilars

Ensemble des articles

Protecting the patents of expensive medicines for longer would affect low-income countries. Jason Reed/ReutersPics

Time for costly medicine monopolies to go from TPP trade talks

Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend.
The cells inside this bioreactor are the real pharmaceutical factories. Sanofi Pasteur

Biologics: The pricey drugs transforming medicine

Rather than being designed by chemists, this class of pharmaceuticals is produced by living cells. Here's where they come from and how they work.
Representatives of the 12 Trans-Pacific Partnership (TPP) member countries at a press conference in Atlanta, after a deal was reached. EPA/Erik S. Lesser

Why biologics were such a big deal in the Trans Pacific Partnership

Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.

Les contributeurs les plus fréquents

Plus